Pusat Penelitian Rumah Sakit Beacon

Pusat Riset

Studi penelitian dan uji coba klinis adalah komponen kunci dari pendekatan penelitian klinis berdasarkan bukti dari pusat penelitian Rumah Sakit Beacon.

Tes uji coba klinis memperbarui pengobatan pasien penderita kanker, seperti: obat baru, kombinasi pengobatan baru, pendekatan baru pembedahan atau terapi radiasi, atau metode baru, seperti terapi gen. Tujuan penelitian ini adalah untuk menemukan cara yang lebih baik dalam mengobati kanker dan menolong pasien kanker.

Studi penelitian dan uji coba klinis adalah komponen kunci dari pendekatan penelitian klinis berdasarkan bukti dari pusat penelitian Rumah Sakit Beacon.

Jika pengobatan baru efektif dalam sebuah studi, ia dapat dijadikan pengobatan standar yang dapat menolong banyak pasien. Umumnya pengobatan standar yang paling efektif sekarang ini berdasarkan pada hasil studi sebelumnya, seperti pada kanker payudara, kolon, rektal dan kanker yang menyerang pada anak-anak.

Pasien yang berpartisipasi dapat terbantu dengan sendirinya melalui pengobatan yang mereka terima. Peserta uji coba mendapatkan pengobatan terbaru dari spesialis kanker dan mereka memperoleh baik pengobatan baru yang telah diuji atau pengobatan standar terbaik yang tersedia untuk kanker yang diderita.

Tidak terdapat jaminan bahwa pengobatan baru yang telah diuji coba tidak akan menimbulkan efek samping ataupun akan memberikan hasil yang baik. Jika pengobatan baru terbukti efektif atau lebih efektif daripada pengobatan standar, peserta uji coba klinis inilah yang pertama merasakan manfaatnya.

Meskipun studi penelitian sangat penting bagi kemajuan pengobatan, pusat penelitian Rumah Sakit Beacon mengutamakan hak, keamanan dan kesejahteraan pasien yang terlibat dalam uji coba klinis. Terlepas dari kenyataan bahwa semua studi klinis kami telah mendapatkan persetujuan dari komite etika medis dan penelitian Kementerian Kesehatan Malaysia, kami juga mematuhi standar praktik klinis local atau internasional yang baik untuk menjaga kepentingan etis pasien uji coba klinis.

Hingga kini, tim onkologi kami telah berpartisipasi dalam berbagai uji coba klinis termasuk membandingkan efektivitas pengobatan kemoterapi yang berbeda; resistansi penghambat; perubahan epigenetik pada kanker nasofaring; dan pengobatan untuk adenocarcinoma pada persimpangan gastroesofagus stadium lanjut atau metastatik.

No.	Judul Protokol	Status
1	InCyte Podium (INCMGA0012-304) A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304)	Aktif (Merekrut)
2	MARIPOSA A Randomized Study of JNJ-61186372 and Lazertinib Combination Therapy Versus Single Agent Osimertinib or Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.	Aktif (Merekrut)
3	ATORG003 A single-arm, open-label, phase 2 study of dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation	Aktif (Merekrut)
4	LAURA A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive on-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA).	Aktif (Merekrut)
5	Invitrocue PDO for drug screening Validating the use of patient-derived organoids for predicting drug response to chemotherapy in patients with advanced solid cancers	Aktif (Merekrut)
6	MS200095-0031-INSIGHT 2 A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior Osimertinib therapy.	Aktif (Merekrut)
7	CBYL719H12301 – EPIK B3 A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation.	Aktif (Merekrut)
8	ATORG 001 A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study).	Aktif (Merekrut)
9	ATORG004 Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer (Investigator Initiated Research)	Aktif (Merekrut)
10	CT-P16 3.1 A double-blind, randomized, active-controlled, parallel-Group, Phase 3 study to compare efficacy and safety of CT-P16 and EU-approved Avastin as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer.	Aktif (Berhenti merekrut)
11	MK7902-007 A Phase III, randomized, double-blind trial of Pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007).	Aktif (Berhenti merekrut)
12	MK3475-394 A Phase III Randomized Double-Blind study of pembrolizumab plus best supportive care as second-line therapy in Asian subjects with previously systematically treated advanced hepatocellular carcinoma	Aktif (Berhenti merekrut)
13	Keynote-590 A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination of cisplatin and 5FU versus placebo in combination with cisplatin and 5FU as first-line treatment in subjects with advanced/metastatic esophageal carcinoma	Aktif (Berhenti merekrut)
14	MK3475-042: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naive Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)	Aktif (Berhenti merekrut)
15	EMR200095-006 Phase Ib/II Multicentre, Randomized Open Label Trial to Compare (MSC2156119J) Combined Gefitinib Versus Chemotherapy as Second Line Treatment in Subject with MET (+), Locally Advanced / Metastatic Non-Small Lung Cancer (NSCLC) Harbouring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor	Aktif (Berhenti merekrut)
16	Tessa FF01: A Multicentre, Randomised, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr virus-specific Autologous Cytotoxic T Lymphocytes vs Gemcitabine andCarboplatin as first line treatment for Advanced NPC	Selesai
17	Hyperthermia – REMISSION 1C Hyperthermia in Treating Patients with Unresectable Abdominal, Pelvic tumours and Cutaneous and Peritoneal Metastases	Selesai
18	TROIKA A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety, and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast cancer	Selesai
19	CLEE011A2404 An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribocliclib (LEE11) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease	Selesai
20	Studies On Epigenetic Changes In Nasopharyngeal Cancer	Selesai
21	Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care	Selesai
22	Healthcare Performance Measurement And Reporting For Breast Cancer Services In Malaysia	Selesai (View Abstract) (View Paper)
23	A Randomized, Phase II, Placebo Controlled Study Of Lacebo Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma	Selesai
24	A Multiple Center, Open-Label, Randomized Phase III Study To Evaluate The Efficacy And Safety Of Erlotinib (Tarceva®) Versus Gemcitabine / Cisplatin As The First-Line Treatment For Stage IIIB / IV Non-Small Cell Lung Cancer (NSCLC) Patients With Mutations In The Tyrosine Kinase Domain Of Epidermal Growth Factor Receptor (EGFR) In Their Tumors.	Selesai
25	An Open-Label, Randomized Phase 3 Study Of The Efficacy And Tolerability Of Linifanib (ABT-869) Versus Sorafenib In Subjects With Advanced Hepatocellular Carcinoma (HCC)	Selesai

Terlepas dari uji coba klinis onkologi, konsultan kami dari pusat-pusat keunggulan lainnya juga memberikan kontribusi pada spesialisasi klinis mereka dengan penelitian mereka yang dipublikasikan.

No	Judul Publikasi	Nama Konsultan	Jenis Presentasi
1	Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care
2	Healthcare Performance Measurement And Reporting For Breast Cancer Services in Malaysia
3	Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical Photographs	Dr Ong Chin Tuan (Consultant Ophthalmologist)	Poster
4	Breast cancer survivorship in an Asian specialist centre from Malaysia: A retrospective analysis	Dato Ibrahim Dr Azura Arkonam Balasubramaniam Manivannan (Consultant Oncologists) Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)	Original Article
5	Presenting complaints of patients and palliative care referral patterns	Dr Felicia Chang Dr Azura Jessica Tan, Ph.D

Jika anda tertarik dan ingin mengetahui lebih lanjut mengenai uji coba klinis yang sedang berlangsung, silahkan hubungi kami di +603 7787 2854 atau anda dapat mengirim email pada kami di clinicalresearch@beaconhospital.com.my.

Search For Consultant

PUSAT KEUNGGULAN